Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients
Authors:
- Gilberto de CastroGCGilberto de Castro
- Miriam Hatsue Honda FedericoMFMiriam Hatsue Honda Federico
- 1 May 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 18 (3) , 266-270
Abstract
As part of the multidisciplinary approach to head and neck cancer patients, radiation therapy plays an essential role, improving locoregional control. Radiation therapy-induced xerostomia is a late side-effect that increases the risk for developing dental caries and compromises oral mucosal integrity, resulting in oral pain, loss of taste, difficulties with swallowing and chewing, sleep disorders and worse quality of life. This review focuses on evaluation, prevention and management of radiation therapy-induced xerostomia. In terms of xerostomia prevention, some clinical trials evaluating amifostine and intensity-modulated radiation therapy have shown positive results. Pilocarpine is a useful agent as a treatment of radiation-induced xerostomia in head and neck cancer patients. Despite some advances in radiation therapy-induced xerostomia prevention, its treatment is an area in which advances are urgently needed.Keywords
This publication has 42 references indexed in Scilit:
- Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: Implications for future trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Long-term parotid gland function after radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Chemoradiation-Induced Cell Loss in Human Submandibular GlandsThe Laryngoscope, 2005
- Serious adverse effects of amifostine during radiotherapy in head and neck cancer patientsRadiotherapy and Oncology, 2004
- Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neckSeminars in Oncology, 2003
- Does amifostine have a role in chemoradiation treatment?The Lancet Oncology, 2003
- ErrataSeminars in Oncology, 2003
- Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapySeminars in Radiation Oncology, 2003